Investor FAQs

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process

Investor FAQs

Show All
What is Relay’s official name?

Relay Therapeutics, Inc.

Where is Relay Therapeutics corporate headquarters?

Relay Therapeutics is headquartered at 399 Binney St, 2nd Floor, Cambridge, MA, 02139. The main phone number is 617-370-8837.

When was the company founded?

Relay Therapeutics was founded in 2015.

Where is Relay Therapeutics incorporated?

Relay Therapeutics is incorporated under the laws of the State of Delaware.

Where is Relay Therapeutics’ common stock listed and what is the ticker symbol?

Relay Therapeutics is listed on the NASDAQ Global Market under the ticker symbol RLAY.

When did Relay Therapeutics go public?

Relay Therapeutics began trading common stock shares on the NASDAQ Global Market on July 16th, 2020.

When is Relay Therapeutics fiscal year-end?

Relay Therapeutics’ fiscal year-end is on December 31.

Who is Relay Therapeutics transfer agent and how do I contact them?

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
US Phone: +1 800 962 4284
International Phone: +1 781 575 312

Who do I contact regarding questions or changes to my stock certificates (including updating a mailing address, replacing my lost stock certificates, etc.)?

For matters related to stock certificates, please contact Relay Therapeutics’ transfer agent:
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021

Who are Relay Therapeutics independent auditors?

Ernst & Young LLP
200 Clarendon Street
Boston, MA 02116

Who is Relay Therapeutics legal counsel?

Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210

Where can I get the latest corporate news releases and financial reports?

Relay Therapeutics’ press release archives can be viewed at

How can I view documents Relay Therapeutics has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?

Relay Therapeutics’ SEC filings can be viewed here.

Whom should I contact if I have further questions?

You can contact Pete Rahmer, Head of Investor Relations at Relay Therapeutics, at